Predicting treatment results for lung cancer before surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a treatment given before surgery for non-small cell lung cancer. Patients receive chemotherapy plus immunotherapy (chemo-immunotherapy) first, then have surgery to remove the tumor. The goal is to see how well this approach works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer, a common type of lung cancer.
- Your treatment plan must include chemotherapy plus immunotherapy (chemo-immunotherapy) before surgery to remove the tumor.
- Your lung cancer cannot have come back after treatment or spread to other parts of the body.
- You must not have another type of cancer that started in a different organ.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial looks at how well different treatments work before surgery for early-stage non-small cell lung cancer (NSCLC). It aims to help doctors understand which pre-surgery therapies lead to the best outcomes.
This study uses CT scan images to help doctors predict which patients with resectable lung cancer will benefit most from receiving chemoimmunotherapy (a combination of chemotherapy and immunotherapy) before surgery. The goal is to personalize treatment planning and improve outcomes.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.